TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04134598

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Breast irradiation (RT)
Description: Irradiation of volume's portion Index quadrant) or whole volume of the residual breast.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Endocrine Therapy (ET): letrozole, anastrozole, exemestane, tamoxifen
Description: Adjuvant endocrine therapy as per local policy (letrozole/anastrozole/exemestane/tamoxifene for 5-year or switch schedules aromatase inhibitors/tamoxifen for 5-year).
Study: NCT05739643

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: FBX-101
Description: A replication-deficient adeno-associated virus gene transfer vector expressing the human galactocerebrosidase (GALC) cDNA will be delivered one-time through a venous catheter inserted into a peripheral limb vein.
Study: NCT05867433

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Usual Care
Description: No STHS program~The usual care group will be offered the same activities as the intervention group after the conclusion of the research study.
Study: NCT05592626

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAR0602
Description: solution, intravenous infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: STAR0602
Description: solution, intravenous infusion
Study: NCT05647915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine plus lifestyle intervention
Description: berberine hydrochloride 500mg twice a day for 6 months plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo plus lifestyle intervention
Description: Placebo with identical shape, colour, odour and taste twice a day plus lifestyle intervention.~Lifestyle intervention is based on Guidelines of prevention and treatment for non-alcoholic fatty liver disease (2018 update) and China Blue Paper on Obesity Prevention and Control, including health education on diet, physical activity and weight loss, etc.
Study: NCT06492707

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Decoy-resistant interleukin-18
Description: Given SC

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration
Study: NCT05949645

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Apreo Implant Group
Description: One or two procedures involving placement of up to three Apreo implants in the bronchial tree of each lung.
Study: NCT06264635

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Platelet-Rich-Plasma
Description: PRP refers to a treatment where a patient's own blood is used to promote healing. Blood is drawn, processed to concentrate the platelets, and then re-injected into the injured area to stimulate tissue repair.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Provider will go through the same motions as injecting PRP, but will use saline instead which has no known effect.
Study: NCT06526195

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS HF System
Description: The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS HF System
Description: The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CardioMEMS HF System
Description: The CardioMEMS™ HF System is comprised of a lead-less and battery-less pressure sensor which remotely transmits pulmonary artery pressure measurements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HeartMate 3 Left Ventricular Assist System
Description: The HeartMate 3 LVAS is a mechanical circulatory support pump with Full MagLev Technology that assumes some or all of the workload of the left ventricle. The HeartMate 3 LVAS is used in advanced heart failure patients needing short or long-term mechanical circulatory support.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guideline Medical Directed Therapy
Description: Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guideline Medical Directed Therapy
Description: Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Guideline Medical Directed Therapy
Description: Optimal doses of medical therapy per established heart failure guidelines which includes the following stable combination of Beta Blockers, ACE-inhibitors or ARB or ARNi, MRA and SGLT2 inhibitors.
Study: NCT05805137

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WoundWatch® wound monitoring system
Description: eDressing will be applied along with the compression therapy and the standard absorbing dressings. The subjects will be monitored using the WoundWatch® system. The subjects will have two to three study visits per week until the venous ulcer has healed (surface area has decreased at least 90%) or up to two months.
Study: NCT05714085

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat tablet
Description: 2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat tablet
Description: 2.5 mg or 5 mg or 10 mg vericiguat administered orally once daily in tablet form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat suspension
Description: 0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vericiguat suspension
Description: 0.2 mg/mL or 1 mg/mL vericiguat administered orally once daily in suspension form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet
Description: Placebo for vericiguat administered orally once daily in tablet form

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo suspension
Description: Placebo for vericiguat administered orally once daily in suspension form
Study: NCT04857164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab combined with Chemotherapy
Description: Pembrolizumab (formerly lambrolizumab, brand name Keytruda) is a humanized antibody used in cancer Chemotherapy regimen is selected by the investigator immunotherapy. This includes to treat melanoma, lung cancer, head and neck cancer, Hodgkin lymphoma, and stomach cancer.
Study: NCT04979806

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefepime-zidebactam (FEP-ZID)
Description: 3 g (2 g FEP + 1 g ZID) IV q8h

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropenem
Description: 1 g IV q8h
Study: NCT05938478

Intervention type: DRUG
Intervention: Tralokinumab
Description: This is a prospective observational cohort study. There is no treatment allocation. Participants that have been exposed to tralokinumab before enrollment into the study will be enrolled.

Intervention type: DRUG
Intervention: Tralokinumab
Description: This is a prospective observational cohort study. There is no treatment allocation. Participants that have been exposed to tralokinumab before enrollment into the study will be enrolled.
Study: NCT05703074

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nicotinamide Riboside (NR)
Description: 4 capsules (a total of 1000 mg) 2 times daily for 84 days

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Nicotinamide Riboside (NR)
Description: 4 capsules (a total of 1000 mg) 2 times daily for 84 days

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mind-body reprocessing therapy (MBRT)
Description: 4-6 face-to-face meetings over 3-4 weeks, unlimited access to designated online resources.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mind-body reprocessing therapy (MBRT)
Description: 4-6 face-to-face meetings over 3-4 weeks, unlimited access to designated online resources.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Care as usual
Description: A brief self-help leaflet on long COVID is distributed, otherwise care as usual by the general practitioner

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Care as usual
Description: A brief self-help leaflet on long COVID is distributed, otherwise care as usual by the general practitioner

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: 4 capsules (empty) 2 times daily for 84 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Placebo
Description: 4 capsules (empty) 2 times daily for 84 days.
Study: NCT06111586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frexalimab
Description: Intravenous (IV) Infusion at Day 1 and subcutaneous (SC) Injection from W2 to W102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frexalimab
Description: Intravenous (IV) Infusion at Day 1 and subcutaneous (SC) Injection from W2 to W102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frexalimab
Description: Intravenous (IV) Infusion at Day 1 and subcutaneous (SC) Injection from W2 to W102

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV Infusion at Day 1 and SC Injection from W2 to W102
Study: NCT04805736

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Camrelizumab 200 mg was given a few days after microwave ablation
Study: NCT06111586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: SC injection, dose and frequency will be established and/or adjusted by investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: SC injection, dose and frequency will be established and/or adjusted by investigator

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: SC injection, dose and frequency will be established and/or adjusted by investigator

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Insulin
Description: SC injection, dose and frequency will be established and/or adjusted by investigator
Study: NCT05144009

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loncastuximab Tesirine
Description: Intravenous (IV) Infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Cycle 1 - Intravenous (IV) Infusion. Cycle 2+ - Intravenous (IV) Infusion or Subcutaneous (SC) Administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Cycle 1 - Intravenous (IV) Infusion. Cycle 2+ - Intravenous (IV) Infusion or Subcutaneous (SC) Administration.
Study: NCT04772937

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LLETZ
Description: LLETZ is one of several possible surgical interventions for treating cervical dysplasia. The transformation zone of the cervix is completely removed

Intervention type: PROCEDURE
Group type: OTHER
Intervention: LEEP
Description: LEEP is one of several possible surgical interventions for treating cervical dysplasia. Only the dysplastic lesion is removed without removing the whole transformation zone.
Study: NCT06015737

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution for injection in aPFS.

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Anifrolumab
Description: Anifrolumab will be provided as a solution for injection in accessorized pre-filled syringe (aPFS).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo solution for injection in aPFS.
Study: NCT06485206

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: One level Mobi-C and one level fusion
Description: Cervical Disc Arthroplasty:~• Mobi-C~Fusion devices:~* One-level cervical plates~  o MaxAn Cervical plate system~* Interbody spacers~  * TrellOss-C - 3D printed Ti interbody~ * Vista-S - PEEK interbody~* Standalone Fixation~  * Ti-Coated ROI-C - PEEK cage w/ Ti coating~ * TrellOss-C SA - 3D printed Ti~* Bone Graft~  * Local Autograft~ * PrimaGen Advanced Allograft
Study: NCT05092282

Intervention type: DEVICE
Intervention: Head and Intraocular Trauma Tool
Description: HITT device to scan eyes of participants up to 3 times (\~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.

Intervention type: DEVICE
Intervention: Head and Intraocular Trauma Tool
Description: HITT device to scan eyes of participants up to 3 times (\~45 seconds each) at time of admittance to study. Participant is to place chin in chin-rest and fixate on illuminated light on device.
Study: NCT05554406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given SC or IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow aspiration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin Hydrochloride
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO
Study: NCT04805736

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Surgery
Description: Standard of care breast conserving surgery or radical mastectmoy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Breast Surgery
Description: Standard of care breast conserving surgery or radical mastectmoy
Study: NCT05554406

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Echocardiography
Description: Undergo ECHO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposome-encapsulated Daunorubicin-Cytarabine
Description: Given IV

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Multigated Acquisition Scan
Description: Undergo MUGA
Study: NCT05092282

Intervention type: DIAGNOSTIC_TEST
Intervention: SCAT-5
Description: Participant is to complete Step 2 (Symptom Evaluation) and Step 3 (Cognitive Screening) of SCAT-5 test.
Study: NCT05554406

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Given PO
Study: NCT06029296

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac
Description: 100 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study: NCT06332534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Solution/ Extended-Release Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Solution/ Extended-Release Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Solution/ Extended-Release Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Solution/ Extended-Release Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Solution/ Extended-Release Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral Solution/ Extended-Release Tablets
Study: NCT06520865

Intervention type: OTHER
Intervention: Acoustic paradigms
Description: Acoustic oddball Gap detection

Intervention type: OTHER
Intervention: Acoustic paradigms
Description: Acoustic oddball Gap detection
Study: NCT06238817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Cream
Description: Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Cream
Description: Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Cream
Description: Ruxolitinib cream applied topically to the affected area as a thin film twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Matching vehicle cream applied topically to the affected area as a thin film twice daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream
Description: Matching vehicle cream applied topically to the affected area as a thin film twice daily.
Study: NCT06232642

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin, iron and B12 in Whey Protein
Description: Chocolate Flavored Whey Protein Isolate Powder with (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
Study: NCT06232642

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin, Iron and B12 in Rice Protein
Description: Chocolate Flavored Rice Protein Isolate with (200mg Lactoferrin, 6mg Iron, 5.2 ug B12)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin, Iron and B12 in Maltrodextrin
Description: Chocolate Flavored (200mg Lactoferrin, 6 mg Iron, 5.2 ug B12)
Study: NCT06144619

Intervention type: GENETIC
Intervention: Genomic and Histological Evaluation
Description: Participants will obtain genomic and histological evaluation on their biopsied samples. (Follows SOC)

Intervention type: GENETIC
Intervention: Genomic and Histological Evaluation
Description: Participants will obtain genomic and histological evaluation on their biopsied samples. (Follows SOC)
Study: NCT06279949

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Provider training
Description: Clinics randomized to a condition involving provider training will receive training on state-specific laws regulating minors' access to confidential HIV testing.
Study: NCT06760637

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: letrozole
Description: endocrine therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: abemaciclib
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: palbociclib
Description: CDK4/6 inhibitor

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribociclib
Description: CDK4/6 inhibitor
Study: NCT06775899

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PC-Based Ultrasound Training Tool
Description: An interactive, PowerPoint-based PC tool designed to simulate pathology recognition and ultrasound image optimization for medical students. It provides real ultrasound videos and images, allowing students to practice diagnostic interpretation and image acquisition in a structured training format.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Ultrasound Simulator (VausSim)
Description: A medium-cost ultrasound simulator used for hands-on training in thoracic and abdominal ultrasound. It allows medical students to practice probe handling, image acquisition, and pathology recognition in a controlled simulation environment.
Study: NCT06777134

Intervention type: OTHER
Intervention: Tibialis anterior muscle activation
Description: The NeuroTrac Myoplus Pro (Quintet, Bergen, Norway) EMG device will be used for the superficial EMG analysis of the tibialis anterior muscle. During the assessment, single-use 30 x 30 mm round adhesive electrodes will be placed on the reference points. The active electrode will be positioned on the muscle body of the tibialis anterior, the passive electrode will be placed 4 cm distal, and the reference electrode will be placed on the lateral malleolus (34,35).~The patient will be asked to perform isometric ankle dorsiflexion against resistance for 10 seconds. The ankle isometric contractions will be performed in 3 repetitions, with a 20-second rest period between contractions. As a result of the assessment, parameters related to the muscle's strength, total work, and resting tone will be recorded in microvolts; the maximal voluntary contraction will be recorded as a percentage.
Study: NCT06777602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] MK-5475
Description: \[14C\] MK-5475 is administered as a single IV bolus dose in healthy male participants on Day 1.